Linked Life Data

21482217

Source:http://linkedlifedata.com/resource/pubmed/id/21482217

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-7-20
pubmed:abstractText
Combination therapy may reduce racial/ethnic differences in response to antihypertensives. In this post-hoc analysis, we evaluated treatment response by race/ethnicity among hypertensive adults enrolled in a 12-week, double-blind study in which patients previously uncontrolled (mean sitting systolic blood pressure [MSSBP] ?150 and <200 mm Hg) on angiotensin receptor blocker (ARB) monotherapy (other than valsartan) for 28 days or more (n = 728) were randomized to amlodipine/valsartan 10/320 mg (intensive) or 5/160 mg (moderate). Treatment-naïve patients (in previous 28 days) or those who failed on a non-ARB first underwent a 28-day run-in period with olmesartan 20 mg or 40 mg, respectively. Hydrochlorothiazide (HCTZ) 12.5 mg was added to both arms at week 4; optional up-titration to 25 mg at week 8 (if MSSBP >140 mm Hg). Intensive treatment provided greater BP lowering versus moderate treatment throughout the study, regardless of race/ethnicity (474 white, 198 African American, 165 Hispanic individuals). Least-square mean reductions from baseline to week 4 in MSSBP (primary outcome) ranged from 20.4 to 23.5 mm Hg (intensive) versus 17.5 to 19.0 mm Hg (moderate), across racial/ethnic subgroups. Both regimens were well tolerated. Amlodipine/valsartan/HCTZ combination therapy was efficacious across racial/ethnic subgroups. Maximal efficacy was obtained with intensive treatment.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1933-1711
pubmed:author
pubmed:copyrightInfo
Copyright © 2011. Published by Elsevier Inc.
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
249-58
pubmed:meshHeading
pubmed-meshheading:21482217-Adult, pubmed-meshheading:21482217-African Americans, pubmed-meshheading:21482217-Aged, pubmed-meshheading:21482217-Amlodipine, pubmed-meshheading:21482217-Antihypertensive Agents, pubmed-meshheading:21482217-Blood Pressure, pubmed-meshheading:21482217-Double-Blind Method, pubmed-meshheading:21482217-Drug Therapy, Combination, pubmed-meshheading:21482217-European Continental Ancestry Group, pubmed-meshheading:21482217-Female, pubmed-meshheading:21482217-Hispanic Americans, pubmed-meshheading:21482217-Humans, pubmed-meshheading:21482217-Hydrochlorothiazide, pubmed-meshheading:21482217-Hypertension, pubmed-meshheading:21482217-Male, pubmed-meshheading:21482217-Middle Aged, pubmed-meshheading:21482217-Receptors, Angiotensin, pubmed-meshheading:21482217-Tetrazoles, pubmed-meshheading:21482217-Valine
pubmed:articleTitle
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.
pubmed:affiliation
Morehouse School of Medicine, Atlanta, Georgia, USA. eofili@msm.edu
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Research Support, N.I.H., Extramural